TTrialPathMatch Me to Trials
← Back to trials
RecruitingTransthyretin Amyloidosis Cardiomyopathy (ATTR-CM)AmyloidosisAmyloid Cardiomyopathy

Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

Eligible age

18–80 yrs

Accepts

All genders

Locations

3 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

Sponsor: Eidos Therapeutics, a BridgeBio company

Where it's recruiting

Maryland

Baltimore

Missouri

St Louis

Pennsylvania

Philadelphia

Source: ClinicalTrials.gov · NCT07695701 · last updated 2026-11-19

Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis · TrialPath